FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: MA-tek Plans to Inject Around NT$700 Million to Upgrade Seven Laboratories

By

Materials analysis firm MA-tek plans to invest around NT$700 million to upgrade seven laboratories across northern and southern Taiwan under government-backed investment schemes, Now News reported Monday.

The upgrades span Hsinchu County, Hsinchu City and Tainan, and will add advanced testing equipment alongside 208 new jobs, according to the report.

The company, which serves semiconductor, display and optoelectronics sectors, is pushing deeper into AI-enabled testing, automated reporting and data-driven management systems. It also plans workflow reviews aimed at improving energy efficiency and establishing a greenhouse gas inventory framework, the report said.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Asia

Sichuan Jinshi Technology to Cancel Nearly 2 Million Restricted Shares

Sichuan Jinshi Technology (SHE:002951) will repurchase and cancel 1.9 million restricted shares, or 0.48% of its total share capital, after failing to meet 2025 performance targets.The cancellation will reduce total shares to 403.1 million from 405 million and cut registered capital by 1.9 million yuan to 403.1 million yuan, according to a Monday filing with the Shenzhen bourse.The move affects 30 incentive recipients.Shares of the paper packaging company closed 10% higher Monday.

$SHE:002951
Asia

Fitch Upgrades Kioxia to BBB- on Financial Profile Boost

Fitch Ratings raised Kioxia Holdings' (TYO:285A) issuer default rating to BBB- from BB+, with a stable outlook, according to a Monday release.The rating action considers the boost in the Japanese company's financial profile on a mid-cycle basis given improved operating performance, solid cash generation, and reduced funding costs after refinancing its debt, Fitch said.The company has shown strong EBITDA profitability, resulting to positive free cash flow generation and EBITDA leverage kept at under 0.5x, the rating agency said.The company now has improved capacity to weather volatility in the NAND memory semiconductor cycle, Fitch said.The rating reflects the company's major position in the NAND industry, driven by advanced technological capability, resilient cost competitiveness, and high barriers to entry.Notable shifts in the company's market share, profit margin, EBITDA leverage, and cash flow could prompt future rating actions.

$TYO:285A
Asia

Yabao Pharmaceutical Subsidiary Secures Chinese Regulatory Approval for High Cholesterol Tablets

China's drug regulator granted Yabao Pharmaceutical's (SHA:600351) Beijing subsidiary a drug registration certificate for its ezetimibe tablets, according to a Saturday filing with the Shanghai bourse.Beijing Yabao Biopharmaceutical's drug treats high cholesterol levels by absorbing cholesterol in the intestine, the pharmaceutical company said in its filing.

$SHA:600351